Nasopharyngeal Carcinoma
📧 Sign up to get email alerts when something new happens for Nasopharyngeal Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
EMA authorised Loqtorzi (toripalimab) for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers [Phase 2, Phase 3]
Phase 2/3 trial evaluating atezolizumab and/or bevacizumab with or without standard chemotherapy as second-line treatment for advanced head …
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era [Phase 3]
A Phase 3 trial evaluating concurrent chemotherapy with intensity-modulated radiotherapy for intermediate-risk nasopharyngeal carcinoma has …
-
EMA approval · 2026-04-22EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
Loqtorzi (toripalimab) has been authorised in the European Union for nasopharyngeal carcinoma and esophageal squamous cell carcinoma. It is …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. [Phase 3]
A Phase 3 clinical trial from Sun Yat-sen University evaluating GAPP induction followed by concurrent chemoradiotherapy for high-risk locore…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2026-04-17Clinical Trial Update: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) [Phase 3]
A phase 3 trial comparing BL-B01D1 with physician's choice chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma; c…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer [Phase 2]
Phase 2 trial evaluating nivolumab and ipilimumab with or without cabozantinib for recurrent or metastatic nasopharyngeal carcinoma is curre…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) [Phase 2]
Phase 2 clinical trial evaluating nivolumab in combination with chemotherapy for nasopharyngeal carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer [Phase 2]
Phase 2 trial evaluating cemiplimab plus CDX-1140 given before surgery to determine if the combination improves outcomes versus cemiplimab a…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers [Phase 1, Phase 2]
A Phase Ib/II clinical trial evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for advance…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma [Phase 2]
Phase 2 clinical trial investigating maintenance therapy with tislelizumab and metronomic capecitabine in high-risk locoregionally-advanced …
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC [Phase 2]
A Phase 2 clinical trial evaluating a PD-1 monoclonal antibody in combination with gemcitabine and cisplatin, followed by selective radiothe…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 3]
Phase 3 trial evaluating Becotatug Vedotin (MRG003) in combination with a PD-1 blocker and chemoradiotherapy for high-risk locoregionally ad…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer [Phase 2]
A Phase 2 clinical trial is evaluating adding relatlimab to standard immunotherapy for recurrent or metastatic nasopharyngeal carcinoma, and…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC [Phase 2]
A phase 2 trial evaluating low-dose radiotherapy combined with toripalimab and chemotherapy for recurrent or metastatic nasopharyngeal carci…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy [Phase 2]
A Phase 2 clinical trial evaluating Becotatug Vedotin for locally advanced nasopharyngeal carcinoma with suboptimal response to induction ch…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]
Phase 2 trial evaluating TQB2618 in combination with Penpulimab for recurrent/metastatic nasopharyngeal carcinoma has completed. Sponsor: Ch…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. [Phase 3]
Phase 3 clinical trial comparing reduced-dose versus standard-dose irradiation for low-risk clinical target volume in nasopharyngeal carcino…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA [Phase 2, Phase 3]
Clinical trial update on a phase 2/3 study using EBV DNA-guided, individualized treatment for stage II-IVB nasopharyngeal carcinoma; the tri…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma [EARLY_Phase 1]
An early-phase clinical trial evaluating Epstein-Barr virus-targeted CAR-T/TCR-T cell therapy for nasopharyngeal carcinoma, currently recrui…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: LDRT and Chemoimmunotherapy in NPC With Liver Metastasis [Phase 2]
Phase 2 clinical trial evaluating low-dose radiotherapy in combination with chemoimmunotherapy for nasopharyngeal carcinoma with liver metas…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is planned to evaluate the use of allogeneic natural killer (NK) cells in high-risk advanced stage III-IV n…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study
This completed retrospective study assesses upfront neck dissection before radiotherapy for patients with stage N3 nasopharyngeal carcinoma.…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating chidamide in combination with toripalimab and anlotinib for recurrent/metastatic nasopharyngeal carcinoma; t…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC [Phase 3]
A Phase 3 trial from Sun Yat-sen University is evaluating Cadonilimab in combination with low-dose radiotherapy and chemotherapy for nasopha…